Patents Assigned to AnaptysBio, Inc.
  • Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 11753472
    Abstract: Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM 3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: September 12, 2023
    Assignees: Tesaro, Inc., Anaptysbio, Inc.
    Inventors: David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
  • PD-1 AGONIST AND METHOD OF USING SAME
    Publication number: 20220235132
    Abstract: Provided is a PD-1-binding agent comprising an immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide, as well as related compositions and methods for making and using same.
    Type: Application
    Filed: June 4, 2020
    Publication date: July 28, 2022
    Applicant: AnaptysBio, Inc.
    Inventors: Marilyn KEHRY, Stephen PARMLEY, Robert P. MORSE, Gregory N. GOLD, Janean FISHER, Martin Edward DAHL, Margaret Habash MARINO, Rupal KALAPANDA
  • Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 11352427
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 7, 2022
    Assignee: ANAPTYSBIO, INC.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
    Publication number: 20210388095
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Applicant: AnaptysBio, Inc.
    Inventors: Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
  • Antibodies directed against programmed death-1 (PD-1)
    Patent number: 11155624
    Abstract: The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 26, 2021
    Assignees: ANAPTYSBIO, INC., Tesaro, Inc.
    Inventors: David J. King, Marilyn Kehry, Baochuan Huang
  • Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)
    Patent number: 11130814
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: September 28, 2021
    Assignee: AnaptysBio, Inc.
    Inventors: Peter Bowers, Andrew John McKnight, David J. King, Marco Londei
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33)
    Publication number: 20210040198
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Applicant: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Antibodies directed against lymphocyte activation gene 3 (LAG-3)
    Patent number: 10836824
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: November 17, 2020
    Assignee: ANAPTYSBIO, INC.
    Inventors: Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King
  • Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)
    Patent number: 10836820
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: November 17, 2020
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Antibodies directed against programmed death-1 (PD-1)
    Patent number: 10738117
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: August 11, 2020
    Assignee: ANAPTYSBIO, INC.
    Inventors: David J. King, Marilyn Kehry
  • ANTI-IL-33 THERAPY FOR ATOPIC DERMATITIS
    Publication number: 20200239562
    Abstract: Methods of treating atopic dermatitis in a patient with an anti-IL-33 antibody, and methods of selecting atopic dermatitis patients for anti-IL-33 therapy.
    Type: Application
    Filed: October 9, 2018
    Publication date: July 30, 2020
    Applicant: AnaptysBio, Inc.
    Inventor: Marco LONDEI
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20200148770
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: October 17, 2019
    Publication date: May 14, 2020
    Applicant: AnaptysBio, Inc.
    Inventors: Marilyn KEHRY, David J. KING, Jean DA SILVA CORREIA
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
    Publication number: 20200087408
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 19, 2020
    Applicant: AnaptysBio, Inc.
    Inventors: Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
  • Antibodies directed against interleukin 36 receptor (IL-36R)
    Patent number: 10526410
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 7, 2020
    Assignee: AnaptysBio, Inc.
    Inventors: Peter Bowers, Andrew John McKnight, David J. King, Marco Londei
  • Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 10508149
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 17, 2019
    Assignee: AnaptysBio, Inc.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE 3 (LAG-3)
    Publication number: 20190256596
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.
    Type: Application
    Filed: May 1, 2019
    Publication date: August 22, 2019
    Applicant: AnaptysBio, Inc.
    Inventors: Helen Toni JUN, Marilyn KEHRY, Peter BOWERS, David J. KING
  • INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR
    Publication number: 20190016795
    Abstract: A method of inhibiting or preventing an allergic reaction, particularly to a food antigen, in a mammal comprising administering to the mammal an IL-33 inhibitor.
    Type: Application
    Filed: January 17, 2017
    Publication date: January 17, 2019
    Applicant: AnaptysBio, Inc.
    Inventor: Marco LONDEI
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33)
    Publication number: 20180346562
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Application
    Filed: July 23, 2018
    Publication date: December 6, 2018
    Applicant: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Antibodies directed against interleukin-33 (IL-33) and methods of making and using
    Patent number: 10059764
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 28, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Antibodies directed against nerve growth factor (NGF)
    Patent number: 9951126
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: April 24, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben